European shares held around one-year highs Thursday, supported by mergers and acquisitions-related optimism, with Johnson & Johnson’s $30 billion deal to buy...
Johnson & Johnson said Friday that is in early talks to buy the Swiss drugmaker Actelion Pharmaceuticals.
Concern persisted over an impending Federal Reserve rate decision, sending European stocks lower for a second day.